HRT and Breast Cancer Risk During Perimenopause: What the Evidence Actually Shows
A clear guide to HRT and breast cancer risk in perimenopause. Covers absolute vs relative risk, progesterone type, and NICE guidelines.
Why Breast Cancer Risk Dominates HRT Conversations
For many women, the question of breast cancer risk is the single biggest barrier to starting HRT during perimenopause. Concerns are understandable, but they are often shaped by headlines from older studies rather than current evidence. The 2002 Women's Health Initiative trial generated widespread alarm, but that research used older combined HRT formulations and included women who were predominantly post-menopausal and older than typical HRT candidates. Subsequent research has significantly refined the picture. Today, the evidence shows that the risk associated with HRT is far more nuanced than early reporting suggested. Risk depends heavily on the type of progestogen used, whether oestrogen is taken alone or combined, how long HRT is used, and individual baseline risk factors. For women in perimenopause, many of whom are in their 40s and early 50s, the absolute risk numbers look very different from what most people assume. Getting to grips with what the data actually shows allows for genuinely informed decision-making rather than decisions based on outdated fear.
Absolute Risk vs Relative Risk: A Crucial Distinction
One of the most important concepts to understand when discussing HRT and breast cancer is the difference between absolute risk and relative risk. Relative risk describes how much more or less likely something is compared to a baseline. Absolute risk tells you how many additional cases occur per 1,000 people over a defined period. Headlines often report relative risk because the numbers sound more dramatic. When a study says HRT increases breast cancer risk by 26 percent, that sounds alarming, but it may represent only a handful of extra cases per thousand women over many years. The 2019 Collaborative Group on Hormonal Factors in Breast Cancer analysis, which pooled data from 58 studies, found that combined oestrogen-progestogen HRT does carry a small increase in absolute risk. For a woman starting combined HRT at 50 and using it for five years, the additional risk is roughly equivalent to having a glass or two of wine daily or being overweight. Oestrogen-only HRT carries little to no increased risk and may even reduce risk slightly in some groups. Contextualising numbers this way helps women weigh HRT against its very real benefits.
Why the Type of Progestogen Matters
Not all progestogens carry the same risk profile. This is one of the most significant findings to emerge from recent research and has directly influenced prescribing guidance. Synthetic progestogens, including medroxyprogesterone acetate (found in older combined HRT formulations) and norethisterone, appear to carry a higher breast cancer risk than body-identical micronised progesterone. The E3N French cohort study, which followed over 80,000 women for years, found that HRT combining oestrogen with micronised progesterone was not associated with any significant increase in breast cancer risk, whereas synthetic progestogens were. Micronised progesterone, available in the UK as Utrogestan, is derived from plant sources and is structurally identical to the progesterone the body makes naturally. NICE clinical guidelines now acknowledge that micronised progesterone may have a more favourable safety profile regarding breast cancer, and many clinicians now prefer it as the progestogen component of HRT. Women who have had a hysterectomy can take oestrogen alone and avoid this consideration altogether.
What NICE Guidelines Currently Recommend
The National Institute for Health and Care Excellence updated its menopause guidelines in 2023, providing clearer direction for prescribers and women considering HRT. NICE recognises that for the majority of women under 60 who are within 10 years of their last period, the benefits of HRT outweigh the risks for most health outcomes. On breast cancer specifically, NICE notes that the risk is small for most HRT types and formulations, and that it needs to be weighed against HRT's protective effects on bone density, cardiovascular health and quality of life. NICE recommends that women be given individualised information about their personal risk rather than blanket statements. It also highlights that the Mirena coil (levonorgestrel IUS) and micronised progesterone carry a lower risk than older synthetic progestogens. NICE explicitly states that a woman with a personal history of breast cancer should be referred to a specialist for shared decision-making rather than being automatically denied HRT. The guidelines represent a significant shift towards nuanced, evidence-based prescribing after years in which fear of breast cancer risk led to under-prescribing.
Individual Risk Factors That Change the Calculation
HRT-related breast cancer risk does not exist in isolation. A woman's baseline risk matters enormously and should be part of any conversation about starting HRT. Factors that raise baseline breast cancer risk include a family history of breast cancer (particularly first-degree relatives), certain genetic mutations such as BRCA1 or BRCA2, a history of high-risk benign breast disease, dense breast tissue, higher alcohol intake, obesity, and older age at first pregnancy. Women with several of these factors may have a meaningfully higher baseline risk, which shifts the risk-benefit calculation. Conversely, women who have never smoked, maintain a healthy weight, are active, and have no significant family history may have a very low baseline risk, making the small additional risk from HRT even smaller in absolute terms. Tools such as the IBIS Breast Cancer Risk Evaluator (Tyrer-Cuzick) can give an estimate of personalised lifetime risk. Sharing this with a GP or menopause specialist, alongside a discussion about HRT type and duration, allows for a truly individual assessment rather than a one-size-fits-all decision.
Balancing Risk Against the Benefits of HRT
The breast cancer risk conversation must happen alongside a frank discussion of what leaving perimenopause symptoms untreated costs a woman in quality of life and long-term health. Severe hot flashes, sleep disruption, mood instability, brain fog, joint pain, and sexual difficulties are not trivial. They affect work, relationships, and mental health. Beyond symptom relief, HRT taken during the perimenopausal window reduces the risk of osteoporosis and fractures, supports cardiovascular health, and may have protective effects on cognitive function. The risk of not treating severe symptoms is also a risk, just one that rarely gets discussed in terms of numbers. For many women, the small absolute increase in breast cancer risk associated with modern HRT formulations, particularly those using transdermal oestrogen and micronised progesterone, is genuinely outweighed by the benefits. The key is that this is a personal decision made with full information, not a blanket policy. Regular breast screening, monthly self-examination, and prompt reporting of any breast changes remain important regardless of whether a woman is using HRT.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.